AP7 RC 2 FCT 24 FEB 2006 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

354. PFUS

U.S. APPLICATION NO. (If known, see 37 CE)

see 37 CFR 1.5) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2004/030743 September 2004 19 September TITLE OF INVENTION AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS APPLICANT(S) FOR DO/EO/US Haolun Jin, Chounglu. Kim and Peter H. Nelson Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. IX I The US has been elected (Article 31). X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. c. X is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

IAPS Rec'd PCT/PTO 24 FEB 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICA	TION NO. 11 know	569655	PCT/US2004/0			DOCKET NUMBER
	r items or informati		1 617 03200 47 0	30743	J 334	. PFUS
The fo	llowing fees have b	peen submitted			CALCULATIONS	PTO USE ONLY
21. X Basic national fee (37 CFR 1.492(a))					\$ 300.00	
If the written opi	mination fee (37 Control of the cont	\$ 200.00				
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$ 400.00	
	TOTAL OF 21, 22		in paper over 100 sheets (ex		900.00	
electron The fee Total Sheets	ic medium) (37 CF is \$250 for each ac Extra Sheets	R 1.492(j)). Iditional 50 sheets Number of each a	.821(c) or (e) or computer proof paper or fraction thereof. dditional 50 or fraction p to a whole number)	ogram listing in an	-	
174 100 = 74 /50 = 2 x \$250 Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).					\$ 500.00	
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims	6	5 - 20 =	45	x \$ 50	\$ 2250.00	
ndependent cla	ims :	2 - 3 =	0	× \$200	\$	
MULTIPLE DEP	ENDENT CLAIM(S	6) (if applicable)		+ \$360	\$	
TOTAL OF ABOVE CALCULATIONS =					\$ 3650.00	
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.						
				SUBTOTAL =	\$	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$	
TOTAL NATIONAL FEE =					\$ 3650.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$	
		\$ 3650.00	<u> </u>			
					Amount to be refunded:	\$
					Amount to be charged	\$

IAP5 Rec'd PCT/PTO 24 FEB 2006

10/569655

AP5 HGC O PULLIPIU 24 F E.D 2000
PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$ to cover the above	fees is enclosed.					
Please charge my Deposit Account No. <u>07-1250</u> in the amount of \$ 3650.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. \blacksquare The Commissioner is hereby authorized to charge any additional fees which Account No. $\underline{07-1250}$. A duplicate copy of this sheet is enclosed.						
d. Fees are to be charged to a credit card. WARNING : Information on this form be included on this form. Provide credit card information and authorization	Fees are to be charged to a credit card. WARNING : Information on this form may become public. Credit card information should not be included on this form . Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.						
SEND ALL CORRESPONDENCE TO: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 Attn: Intellectual Property Customer No. 25000	SIGNATURE Allan N. Kutzenco NAME 38,945 REGISTRATION NUMBER					

IAP5 Rec'd PCT/PTO 24 FEB 2006

PATENT COOPERATION TREATY IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re U.S. NATIONAL APPLICATION of) Agent's File Ref. 354.PFUS
Jin et al.)
Jii et al.) Customer No. 25000
U.S. National Filing of International)
Application No.: PCT/US2004/030743)
International Filing Date: 17 September 2004)
For: AZA-QUINOLINOL PHOSPHONATE.)
INTEGRASE INHIBITOR COMPOUNDS)

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Express Mail Mailing Label No. EV 382652110 US

Date of Deposit: February 24, 2006

I hereby certify that the attached Transmittal Letter, Declaration, and Self-Addressed Postcard are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Torres